Evidence map›Paper›PMID 41067164›Full record

GuidelineESMO open2025

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.

D Tai, T Conroy, J J X Lee, C E Chee, C-Y Hao, I Wijaya, S Aggarwal, M Ueno, H-C Jeung, N M Hashim and 20 more

Abstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

D TaiDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Electronic address: david.tai.w.m@singhealth.com.sg.
T ConroyDepartment of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, Nancy, France; Université de Lorraine, INSERM INSPIIRE, Nancy, France.
J J X LeeDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
C E CheeDepartment of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
C-Y HaoDepartment of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
I WijayaDivision of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, Indonesia.
S AggarwalDepartment of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.
M UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
H-C JeungDivision of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
N M HashimOncology and Radiotherapy Department, KPJ Johor Specialist Hospital, Johor Bahru, Malaysia.
J Tan Chun BingTan Kim Ching Cancer Center, Vincente Gullas Memorial Hospital, Cebu City, The Philippines.
L-T ChenKaohsiung Medical University Hospital, Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
K KorphaisarnDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
S TanasanvimonDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
W-C ChouDepartment of Hematology and Oncology, Chang Gung University, Chang Gung Memorial Hospital at Linkou and College of Medicine, Taoyuan, Taiwan.
E CargulloUniversity of Perpetual Help Dalta Medical Center, Las Piñas, The Philippines.
N F A MuinRadiotherapy and Oncology Department, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
M A LeeDivision of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
A OhbaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
S BondardeDepartment of Oncology, Apex Wellness Hospital, Nashik, Maharashtra, India.
C R A LesmanaHepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia.
L WangDepartment of Oncology, Renji Hospital, School of Medicine, Shanghai, China.
E C SmythOxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom.
T YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
G BonneyDivision of Surgical Oncology, National Cancer Institute Singapore, National University Hospital, Singapore; iHealthtech National University of Singapore, Singapore, Singapore.
G PentheroudakisESMO, Lugano, Switzerland.
J SamolDepartment of Medical Oncology, Tan Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Johns Hopkins University, Baltimore, USA.
A CervantesDepartment of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia; CIBERONC. Instituto de Salud Carlos III, Madrid, Spain.
E PoonDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
M DucreuxUniversité Paris-Saclay, Villejuif; Department of Cancer Medicine, Gustave Roussy, INSERM U1279, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer, published in November 2023, were adapted in December 2024, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with pancreatic cancer. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with pancreatic cancer representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Singapore Society of Oncology (SSO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with pancreatic cancer across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in drug approvals and reimbursement strategies between the different countries.

Indexed as

Pancreatic NeoplasmsAsiaHumansMedical OncologySocieties, MedicalESMOguidelinesPan-Asianpancreatic cancertreatment

Identifiers

PMID41067164
PMCPMC12546840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.